Nitric oxide synthase genes and their interactions with environmental factors in Parkinson’s disease

Nitric oxide synthase (NOS) genes (NOS1, NOS2A, and NOS3) may create excess nitric oxide that contributes to neurodegeneration in Parkinson’s disease (PD). NOS genes might also interact with one another or with environmental factors in PD. Coding and tagging single nucleotide polymorphisms (SNPs) (27 NOS1, 18 NOS2A, and five NOS3 SNPs) were genotyped in families with PD (1,065 cases and 1,180 relative and other controls) and were tested for allelic associations with PD using the association in the presence of linkage test and the pedigree disequilibrium test (PDT), allelic associations with age-at-onset (AAO) using the quantitative transmission disequilibrium test, and interactions using the multifactor dimensionality reduction—PDT. Gene–environment interactions involving cigarette smoking, caffeine, nonsteroidal anti-inflammatory drugs, and pesticides were examined using generalized estimating equations in participants with environmental data available. Significant associations with PD were detected for the NOS1 SNPs rs3782218, rs11068447, rs7295972, rs2293052, rs12829185, rs1047735, rs3741475, and rs2682826 (range of p = 0.00083–0.046) and the NOS2A SNPs rs2072324, rs944725, rs12944039, rs2248814, rs2297516, rs1060826, and rs2255929 (range of p = 0.0000040–0.047) in earlier-onset families with sporadic PD, and some SNPs were also associated with earlier AAO. There was no compelling statistical evidence for gene–gene interactions. However, of the significantly associated SNPs, interactions were found between pesticides and the NOS1 SNPs rs12829185, rs1047735, and rs2682826 (range of p = 0.012–0.034) and between smoking and the NOS2A SNPs rs2248814 (p = 0.021) and rs1060826 (p = 0.013). These data implicate NOS1 and NOS2A as genetic risk factors for PD and demonstrate that their interactions with established environmental factors may modulate the environmental effects.

[1]  Yi-Ju Li,et al.  Methods for interaction analyses using family‐based case‐control data: conditional logistic regression versus generalized estimating equations , 2007, Genetic epidemiology.

[2]  Y. Agid,et al.  Nitric oxide synthase and neuronal vulnerability in parkinson's disease , 1996, Neuroscience.

[3]  Gudmundur A. Thorisson,et al.  The International HapMap Project Web site. , 2005, Genome research.

[4]  Eden R Martin,et al.  No gene is an island: the flip-flop phenomenon. , 2007, American journal of human genetics.

[5]  Ted M. Dawson,et al.  Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease , 1999, Nature Medicine.

[6]  Mark Daly,et al.  Haploview: analysis and visualization of LD and haplotype maps , 2005, Bioinform..

[7]  E R Martin,et al.  Genotype‐based association test for general pedigrees: The genotype‐PDT , 2003, Genetic epidemiology.

[8]  Jason H. Moore,et al.  An application of conditional logistic regression and multifactor dimensionality reduction for detecting gene-gene Interactions on risk of myocardial infarction: The importance of model validation , 2004, BMC Bioinformatics.

[9]  Eden R Martin,et al.  Pesticide exposure and risk of Parkinson's disease: A family-based case-control study , 2008, BMC neurology.

[10]  G. Bing,et al.  Up-regulation of inducible nitric oxide synthase in the substantia nigra by lipopolysaccharide causes microglial activation and neurodegeneration , 2003, Neurobiology of Disease.

[11]  J. Dichgans,et al.  Deficiency of Inducible Nitric Oxide Synthase Protects Against MPTP Toxicity In Vivo , 2000, Journal of neurochemistry.

[12]  Mahlon R DeLong,et al.  Prevalence, etiology, and treatment of depression in Parkinson’s disease , 2003, Biological Psychiatry.

[13]  W. Willett,et al.  Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. , 2003, Archives of neurology.

[14]  E R Martin,et al.  Letter to the Editor Correcting for a Potential Bias in the Pedigree Disequilibrium Test , 2022 .

[15]  W. Scott,et al.  Smoking, caffeine, and nonsteroidal anti-inflammatory drugs in families with Parkinson disease. , 2007, Archives of neurology.

[16]  M. Ebadi,et al.  Peroxynitrite and mitochondrial dysfunction in the pathogenesis of Parkinson's disease. , 2003, Antioxidants & redox signaling.

[17]  J. H. Moore,et al.  A novel method to identify gene–gene effects in nuclear families: the MDR‐PDT , 2006, Genetic epidemiology.

[18]  J. Stamler,et al.  A mechanism of paraquat toxicity involving nitric oxide synthase. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T. Foroud,et al.  Reliability of reported age at onset for Parkinson's disease , 2003, Movement disorders : official journal of the Movement Disorder Society.

[20]  E R Martin,et al.  Identification of significant association and gene-gene interaction of GABA receptor subunit genes in autism. , 2005, American journal of human genetics.

[21]  B S Weir,et al.  A comparative study of sibship tests of linkage and/or association. , 1998, American journal of human genetics.

[22]  F. Coppedè,et al.  Genes and the Environment in Neurodegeneration , 2006, Bioscience reports.

[23]  Miguel A Hernán,et al.  A meta‐analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease , 2002, Annals of neurology.

[24]  Y. Shugart,et al.  An evaluation of power and type I error of single-nucleotide polymorphism transmission/disequilibrium-based statistical methods under different family structures, missing parental data, and population stratification. , 2007, American journal of human genetics.

[25]  Eden R Martin,et al.  Accounting for linkage in family-based tests of association with missing parental genotypes. , 2003, American journal of human genetics.

[26]  A. Lees,et al.  Ageing and Parkinson's disease: substantia nigra regional selectivity. , 1991, Brain : a journal of neurology.

[27]  J. H. Moore,et al.  Multifactor-dimensionality reduction reveals high-order interactions among estrogen-metabolism genes in sporadic breast cancer. , 2001, American journal of human genetics.

[28]  S. Gabriel,et al.  Efficiency and power in genetic association studies , 2005, Nature Genetics.

[29]  P. Amouyel,et al.  Association between Parkinson's disease and polymorphisms in the nNOS and iNOS genes in a community-based case-control study. , 2003, Human molecular genetics.

[30]  D. Berg,et al.  Comprehensive association analysis of the NOS2A gene with Parkinson disease , 2006, Neurology.

[31]  J. Witte,et al.  Asymptotic bias and efficiency in case-control studies of candidate genes and gene-environment interactions: basic family designs. , 1999, American journal of epidemiology.

[32]  P. Silburn,et al.  Parkinson's disease and family history. , 2006, Parkinsonism & related disorders.

[33]  T. Dawson,et al.  Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[34]  S. Khuder,et al.  Environmental risk factors and Parkinson's disease: a metaanalysis. , 2001, Environmental research.

[35]  Eric Jacobs,et al.  Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease , 2005, Annals of neurology.

[36]  Hermona Soreq,et al.  Gene–environment interactions in sporadic Parkinson's disease , 2006, Journal of neurochemistry.

[37]  Werner J. Schmidt,et al.  Chronic administration of rotenone increases levels of nitric oxide and lipid peroxidation products in rat brain , 2004, Experimental Neurology.

[38]  K. Soliman,et al.  Inhibitory effects of cigarette smoke on glial inducible nitric oxide synthase and lack of protective properties against oxidative neurotoxins in vitro. , 2005, Neurotoxicology.

[39]  Yi-Ju Li,et al.  NOS2A and the modulating effect of cigarette smoking in Parkinson's disease , 2006, Annals of neurology.

[40]  M. Colasanti,et al.  The dual personality of NO. , 2000, Trends in pharmacological sciences.

[41]  N. Wood,et al.  Understanding the molecular causes of Parkinson's disease. , 2006, Trends in molecular medicine.

[42]  V. Álvarez,et al.  No association between Parkinson's disease and three polymorphisms in the eNOS, nNOS, and iNOS genes , 2007, Neuroscience Letters.

[43]  M. Colasanti,et al.  Cross-talk between constitutive and inducible NO synthase: an update. , 2006, Antioxidants & redox signaling.

[44]  E. Martin,et al.  A test for linkage and association in general pedigrees: the pedigree disequilibrium test. , 2000, American journal of human genetics.

[45]  A. Singleton,et al.  Confirmation of the protective effect of iNOS in an independent cohort of Parkinson disease , 2004, Neurology.